Lyophilized DSIP as Growth Hormone Peptides Delta Sleep-Inducing
Peptide for bodybuilding
Delta sleep-inducing peptide, abbreviated DSIP, is a neuropeptide
that when infused into the mesodiencephalic ventricle of recipient
rabbits induces spindle and delta EEG activity and reduced motor
Its amino acid sequence is Тrр-Аlа-Gly-Gly-Asp-Ala-Ser-Gly-Glu.
However, the gene is unknown , raising serious
questions regarding the actual existence of this peptide in nature.
Synonyms: Delta Sleep-Inducing Peptide
CAS No.: 62568-57-4
Molecular Formula: C35H48N10O15
Molecular Mass: 848.34 Da (g/mol)
DSIP has a peptide purity level that exceeds 99.0% as determined by
- Application Information
Delta sleep-inducing peptide was first discovered in 1974 by the
Swiss Schoenenberger-Monnier group who isolated it from the
cerebral venous blood of rabbits in an induced state of sleep. It
was primarily believed to be involved in sleep regulation due to
its apparent ability to induce slow-wave sleep in rabbits, but
studies on the subject have been contradictory.
Many roles for DSIP have been suggested following research carried
out using peptide analogues with a greater molecular stability and
through measuring DSIP-like immunological (DSIP-LI) response by
injecting DSIP antiserum and antibodies.
Roles in endocrine regulation
> Decreases basal corticotropin level and blocks its release.
> Stimulates release of luteinizing hormone (LH).
> Stimulates release of somatoliberin and somatotrophin
secretion and inhibits somatostatin secretion
Roles in physiological processes
> Can act as a stress limiting factor
> May have a direct or indirect effect on body temperature and
> Can normalize blood pressure and myocardial contraction.
> It has been shown to enhance the efficiency of oxidative
phosphorylation in rat mitochondria in vitro, suggesting it may
have antioxidant effects.
> There is also conflicting evidence as to its involvement in
sleep patterns. Some studies suggest a link between DSIP and
slow-wave sleep (SWS) promotion and suppression of paradoxical
sleep, (PS) while some studies show no correlation. Stronger
effects on sleep have been noted for the synthesized analogues of
> It may have an impact on human lens epithelial cell function
via the MAPK pathway, which is involved in cell proliferation,
differentiation, motility, survival, and apoptosis.
Roles in disease and medicine
> It has been found to have anticarcinogenic properties. In a
study on mice, injecting a preparation of DSIP over the mice's
lifetime decreased total spontaneous tumor incidence 2.6-fold.
> The same study found it to also have geroprotective effects:
it slowed down the age-related switching-off of oestrous function;
it decreased by 22.6% the frequency of chromosome aberrations in
bone marrow cells and it increased by 24.1% maximum life span in
comparison with the control group.
> Levels of DSIP may be significant in patients diagnosed with
major depressive disorder (MDD). In several studies, levels of DSIP
in the plasma and cerebrospinal fluid are significantly deviated
from the norm in patients with MDD, though there are contradictions
as to whether levels are higher or lower than healthy control
> Studies have demonstrated a direct link between GILZ
expression (homologous to DSIP) and adipogenesis which has links to
obesity and metabolic syndrome.
> In studies on rats with metaphit-induced epilepsy DSIP acted
as an anticonvulsant, significantly decreasing the incidence and
duration of fits suggesting DSIP as a potential treatment for
> DSIP has been found to have an analgesic effect. In studies on
mice it was found to have a potent antinociceptive effect when
administered intracerebroventricularly or intracisternally (see:
Route of administration).
> Due to its possible effects on sleep and nociception, trials
have been carried out to determine whether DSIP can be used as an
anaesthetic. One such study found that administration of DSIP to
humans as an adjunct to isoflurane anaesthesia actually increased
the heart rate and reduced the depth of anaesthesia instead of
deepening it as expected.
> Low plasma concentrations of DSIP have been found in patients
with Cushing's syndrome.
> In Alzheimer's patients levels of DSIP have been found to be
slightly elevated, though this is unlikely to be causal.
> A preparation of DSIP, Deltaran, has been used to correct
central nervous system function in children after antiblastomic
therapy. Ten children aged 3–16 years were given a ten-day course
of Deltaran and their bioelectric activity recorded. It was found
that the chemotherapy-induced impairment in the bioelectrical
activity of 9 out of the 10 children was reduced by administration
> DSIP can act antagonistically on opiate receptors to
significantly inhibit the development of opioid and alcohol
dependence and is currently being used in clinical trials to treat
withdrawal syndrome. In one such trial it was reported that in 97%
of opiate-dependent and 87% of alcohol-dependent patients the
symptoms were alleviated by DSIP administration.
> In some studies administration of DSIP has alleviated
narcolepsy and normalized disturbed sleeping patterns.
- Buy DSIP (Delta Sleep-Inducing Peptide) from Biopro for discount on the first order.
- Reference List of Available Peptides
|ACE-931||1 mg||Semorelin||2 mg|
|AOD-9604||5 mg||TB-500||5 mg|
|BPC-157||5 mg||Tesamorelin||10 mg|
|CJC-1295 DAC||2 mg||Triptorein||2 mg|
|CJC-1295 no DAC||2 mg||Melanotan I||10 mg|
|Epithalon||10 mg||Melanotan II||10 mg|
|FST-344||1 mg||PT-141||10 mg|
|Fragment 176-191||5 mg||MGF||2 mg|
|GHRP-2||5 mg||PEG-MGF||2 mg|
|GHRP-6||5 mg||Selank||5 mg|
|Gonadorelin||10 mg||DSIP||2 mg|
|Hexarelin||2 mg||IGF-1 LR3||0.1 mg|
|Ipamorelin||2 mg||IGF-1 (1-3)||1 mg|
|Oxytocin||10 mg||SNAP-8||200 mg|